{Reference Type}: Journal Article
{Title}: Role of hematological and neurological expressed 1 (HN1) in human cancers.
{Author}: Li H;Fan S;Gong Z;Chan JYK;Tong MCF;Chen GG;
{Journal}: Crit Rev Oncol Hematol
{Volume}: 201
{Issue}: 0
{Year}: 2024 Sep 9
{Factor}: 6.625
{DOI}: 10.1016/j.critrevonc.2024.104446
{Abstract}: Hematological and neurological expressed 1 (HN1), also known as Jupiter microtubule associated homolog 1 (JPT1), is a highly conserved protein with widespread expression in various tissues. Ectopic elevation of HN1 has been observed in multiple cancers, highlighting its role in tumorigenesis and progression. Both proteomics and transcriptomics reveal that HN1 is closely associated with severe disease progression, poor prognostic and shorter overall survival. HN1's involvement in cancer cell proliferation and metastasis has been extensively investigated. Overexpression of HN1 is associated with increased tumor growth and disease progression, while its depletion leads to cell cycle arrest and apoptosis. The pivotal role of HN1 in cancer progression, particularly in proliferation, migration, and invasion, underscores its significance in cancer metastasis. Validation of the efficacy and safety of HN1 inhibition, along with the development of diagnostic methods to determine HN1 expression levels in patients, is essential for the translation of HN1-targeted therapies into clinical practice. Overall, HN1 emerges as a valuable prognostic marker and therapeutic target in cancer, and further investigations hold the potential to improve patient outcomes by impeding metastasis and enhancing treatment strategies.